{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:05Z","timestamp":1790173745415,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T00:00:00Z","timestamp":1388361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant melanoma is a highly aggressive cancer with a very poor prognosis after the onset of metastasis. We have previously demonstrated that the protein melanoma inhibitory activity (<jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content>) is involved in the metastasis of and immunosuppression in malignant melanoma. Recently, we further established <jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content> as a therapeutic target to inhibit metastatic spread in malignant melanoma. We could show that an inhibition of <jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content> by a synthetic peptide decreased both the number of metastases as well as immunosuppression in a murine model of malignant melanoma. To control recurrence after surgical resection of a primary lesion, it is paramount to have diagnostic tools available that can detect a relapse due to the strong metastatic potential of melanoma. This follow\u2010up is maintained with periodic re\u2010examinations. Due to high cost and the associated radiation exposure, radiology examinations are avoided if possible. The analysis of prognostic markers in patient serum is therefore attractive. In this review, we focus on the quantitative analysis of the <jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content> protein as a prognostic tool because it has proven to be a useful serum marker for documenting disease progression of malignant melanoma. The <jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content> quantification assay itself is readily performed using an <jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content> kit and common laboratory equipment. Because analysing <jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content> serum levels in combination with other established markers such as <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>100<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> improves their prognostic value, we feel that the quantification of <jats:styled-content style=\"fixed-case\">MIA<\/jats:styled-content> in the serum, among other markers, should be performed as a general standard of care in patients at risk of developing metastatic melanoma.<\/jats:p>","DOI":"10.1111\/exd.12281","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T20:42:01Z","timestamp":1383684121000},"page":"12-14","source":"Crossref","is-referenced-by-count":23,"title":["Melanoma inhibitory activity in melanoma diagnostics and therapy \u2013 a small protein is looming large"],"prefix":"10.1111","volume":"23","author":[{"given":"Alexander","family":"Riechers","sequence":"first","affiliation":[{"name":"Institute of Pathology University of Regensburg Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Katrin","family":"Bosserhoff","sequence":"additional","affiliation":[{"name":"Institute of Pathology University of Regensburg Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"5695","volume":"54","author":"Blesch A","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000097191.12477.5D"},{"key":"e_1_2_7_4_1","first-page":"5041","volume":"20","author":"Stahlecker J","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1424"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200108000-00013"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24508"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2010.121"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M511367200"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20549"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.3.340"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014961408029"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.091601698"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920308784534014"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01565.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01386.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037941"},{"key":"e_1_2_7_18_1","first-page":"421","volume":"28","author":"Schmidt J","year":"2013","journal-title":"Histol Histopathol"},{"key":"e_1_2_7_19_1","first-page":"3149","volume":"57","author":"Bosserhoff A K","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_7_20_1","first-page":"2691","volume":"19","author":"Bosserhoff A K","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00889.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328347105e"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-011-0218-x"},{"key":"e_1_2_7_24_1","first-page":"1311","volume":"21","author":"Kr\u00e4hn G","year":"2001","journal-title":"Anticancer Res"},{"key":"e_1_2_7_25_1","first-page":"2203","volume":"20","author":"Djukanovic D","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01219.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283021929"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27991"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024632"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328307bf3f"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.2005.00274.x"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fexd.12281","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.12281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:41:04Z","timestamp":1695573664000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.12281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/exd.12281"],"URL":"https:\/\/doi.org\/10.1111\/exd.12281","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,30]]}}}